Researchers explore the potential of cord blood cytokine patterns to identify children at risk of autism, highlighting practical advantages and current scientific challenges in developing early screening tools.
A newborn’s cord blood may one day help clinicians spot which children need closer developmental follow-up, but researchers say the idea is still far from a diagnostic test. In a perspective in Pediatric Research, G. Simonti and I. Koutroulis argue that cytokines, the immune system’s signalling proteins, could offer clues about prenatal development and later autism risk. But the authors also stress that any signal found at birth would need careful validation before it could be used in practice. The broader case for looking at early-life biomarkers is strengthened by earlier work, including the Early Markers for Autism Study, which examined neonatal cytokines and chemokines, and by newer findings from the MARBLES cohort linking specific cord blood cytokine patterns with later autism diagnoses.
The attraction of cord blood is practical as well as scientific. It can be collected immediately after delivery, and it captures a biological snapshot of the final stages of pregnancy without putting the infant through an invasive procedure. Researchers have already shown that immune markers in newborn blood can differ in children who later receive an autism diagnosis, and cord blood studies have reported altered levels of several cytokines, including higher granulocyte colony-stimulating factor and lower interleukin-1 and interleukin-4 in children later diagnosed with autism. Those findings do not prove cause and effect, but they do support the idea that prenatal immune activity may leave measurable traces at birth.
Even so, the science is tangled. Cytokine levels can shift with infection, maternal health, medication, stress, gestational age, delivery complications and how a sample is handled in the lab. That makes it hard to separate a genuine developmental signal from background noise. Simonti and Koutroulis say any future screening tool would need to perform reliably across different populations and clinical settings. Their caution is echoed by research on other cord blood biomarkers, including studies of DNA methylation in newborns later diagnosed with autism, which suggest that early biological changes may be detectable but are not yet ready for routine clinical use.
The most immediate use of such testing, if it ever proves robust, would be earlier monitoring rather than treatment. Researchers and clinicians could use a risk signal to arrange developmental checks, speech and language support, and other services sooner, rather than waiting for difficulties to become obvious. That approach fits with the limited but growing literature on cord blood-based interventions, including a small phase I trial that found autologous cord blood infusions were safe and feasible in young children with autism, while a later review concluded that the evidence remains preliminary. For now, the promise of cord blood lies less in prediction than in the possibility of better-timed support.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
